Suppr超能文献

不同强度的抗维生素K治疗与凝血参数之间的相关性。

Correlation between different intensities of anti-vitamin K treatment and coagulation parameters.

作者信息

Jerkeman A, Astermark J, Hedner U, Lethagen S, Olsson C G, Berntorp E

机构信息

Department for Coagulation Disorders, University Hospital, Malmö, Sweden.

出版信息

Thromb Res. 2000 Jun 15;98(6):467-71. doi: 10.1016/s0049-3848(00)00203-6.

Abstract

In order to study the effect of different intensities of anti-vitamin K treatment on coagulation parameters, 23 patients with venous thromboembolism were given, after the initial treatment period, warfarin at doses giving an International Normalised Ratio of 1.3-2.0 for 4 weeks, and of 1.1-1.3 for another 4 weeks. Blood samples were taken at the end of each of these periods and 4 weeks after the end of warfarin treatment. The vitamin K-dependent coagulation factors VII, IX, and X, as well as the inhibitor protein C and its cofactor protein S, all showed a highly significant correlation with treatment intensity. This was to some extent also true for the coagulation activation markers, prothrombin fragment 1+2 and thrombin-antithrombin complex. Ratios of pro- and anticoagulant factors in some instances showed a decrease at therapeutical (International Normalised Ratio) levels, and also sometimes with reduced warfarin treatment intensity. Taken together, our results encourage further research addressing issues of varying treatment intensity with warfarin and alternative methods for monitoring of anti-vitamin K treatment.

摘要

为研究不同强度的抗维生素K治疗对凝血参数的影响,23例静脉血栓栓塞患者在初始治疗期后,接受了华法林治疗,剂量为使国际标准化比值达到1.3 - 2.0,持续4周,之后剂量调整为1.1 - 1.3,再持续4周。在每个阶段结束时以及华法林治疗结束后4周采集血样。维生素K依赖的凝血因子VII、IX和X,以及抑制蛋白C及其辅因子蛋白S,均与治疗强度呈现高度显著相关性。对于凝血激活标志物凝血酶原片段1 + 2和凝血酶 - 抗凝血酶复合物,在某种程度上也是如此。促凝和抗凝因子的比率在治疗性(国际标准化比值)水平时,有时会降低,在华法林治疗强度降低时也会如此。总体而言,我们的结果鼓励进一步研究华法林不同治疗强度的相关问题以及监测抗维生素K治疗的替代方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验